Numerous clinical trials have been completed with three different PHD inhibitors Roxadustat, Vadadustat, and Daprodustat (DPD) concluding that these orally administrable compounds are effective and safe alternatives to ESAs for anemia treatment in CKD patients. Here, PDC is linked to anemia.